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Abstract
Background: An increasing number of diagnostic evaluations incorporate genetic testing to 
facilitate accurate and timely diagnoses. The increasing number and complexity of genetic tests 
continue to pose challenges in deciding when to test, selecting the correct test(s), and using results 
to inform medical diagnoses, especially for medical professionals lacking genetic expertise. 
Careful consideration of a diagnostic workflow can be helpful in understanding the appropriate 
uses of genetic testing within a broader diagnostic workup.
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Content: The diagnosis of long QT syndrome (LQTS), a life-threatening cardiac arrhythmia, 
provides an example for this approach. Electrocardiography is the preferred means for diagnosing 
LQTS but can be uninformative for some patients due to the variable presentation of the condition. 
Family history and genetic testing can augment physiological testing to inform a diagnosis and 
subsequent therapy. Clinical and laboratory professionals informed by peer- reviewed literature 
and professional recommendations constructed a generalized LQTS diagnostic workflow. This 
workflow served to explore decisions regarding the use of genetic testing for diagnosing LQTS.
Summary and outlook: Understanding the complexities and approaches to integrating genetic 
testing into a broader diagnostic evaluation is anticipated to support appropriate test utilization, 
optimize diagnostic evaluation, and facilitate a multidisciplinary approach essential for achieving 
accurate and timely diagnoses.
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Introduction
A 2015 National Academies report, Improving Diagnosis in Healthcare, reported that as 
many as 5% of US adults receiving outpatient healthcare experience a diagnostic error [1, 2]. 
The report emphasizes the need to improve healthcare provider collaboration, patient 
engagement, and processes. This is particularly true for molecular genetic testing, where 
selection of the most appropriate test and interpretation of results requires specialized 
knowledge. As of 2019, molecular genetic testing is invaluable in diagnosis and 
management of cancer, cardiomyopathy, intellectual disability, rare diseases of unknown 
etiology, and other conditions [3–6].
Integrating genetics into the diagnostic workflow can provide valuable insights into the 
diagnosis and management of the patient. However, the application of genetic principles, 
knowledge of familial health conditions, and understanding the uses and limitations of 
laboratory tests introduces complexity to the diagnosis that requires an integrated, 
coordinated, multidisciplinary approach to achieve an accurate and timely diagnosis. There 
are lessons for clinicians, laboratory professionals, and others in exploring a representative 
diagnostic workflow that illustrates challenges and approaches to patient care when genetics, 
which includes genetic testing, is a component of the diagnostic process. A diagnostic 
workflow for long QT syndrome (LQTS), a condition predisposing to lethal cardiac 
arrhythmia, and sudden cardiac death, provides a good model for exploring these issues 
(Figure 1). The peer-reviewed literature and input from this manuscript’s co-authors that 
included board-certified cardiologists, clinical and laboratory geneticists, and a genetic 
counselor informed the presentation of this workflow developed to reflect a realistic 
diagnostic evaluation that accommodates expected variations in practice [7–15].
LQTS is an arrhythmia disorder of cardiac action potential repolarization characterized by 
the prolongation of the QT interval. LQTS may manifest with polymorphic ventricular 
tachycardia, ventricular fibrillation, and sudden cardiac death in otherwise young and 
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healthy children and adults [16]. LQTS provides a good diagnostic model because of the 
following:
• LQTS is clinically well defined and life threatening.
• LQTS is variable in presentation, making diagnosis and management 
challenging.
• Physiological testing is sufficient to make a diagnosis of LQTS.
• There are life-saving interventions.
• It is important to distinguish heritable from acquired (e.g. drug-induced) during 
the diagnostic evaluation.
• DNA testing can inform a diagnosis when physiologic testing is uninformative.
• Physiological and DNA testing are used to determine LQTS subtypes that may 
influence the choice of therapy.
• Genetic test results can be useful to identify affected relatives.
• Professional guidance is available to inform the clinical evaluation of patients 
with arrhythmias with specific reference to LQTS and use of genetic testing [13].
The variable presentation of LQTS can result in delayed or missed diagnoses [17]. Proper 
diagnosis of LQTS and subsequent therapy have been reported to reduce mortality to around 
1% over a 10-year period [14]. In one report, 39% of patients with LQTS had delayed 
diagnosis after presentation; they received initial diagnoses of epilepsy, breath-holding 
attacks, and vasovagal syncope. Recognition of a family history of LQTS can be lifesaving 
as sudden cardiac death can occur at a young age in the absence of treatment [17]. Similarly, 
efficacious use of genetic testing is useful to establish a diagnosis, identify disease subtypes 
that can influence therapy selection, and to identify other family members at risk for LQTS. 
In summary, LQTS is a highly variable genetic condition for which there are physiological 
diagnostic criteria, and for which DNA testing is useful for diagnosis, therapy selection, and 
identifying risk to other family members.
Clinical and genetic aspects of LQTS
Criteria for diagnosing LQTS are established (Table 1) [13]. LQTS can be heritable or 
acquired. Medication-induced acquired LQTS is the most common cause of the acquired 
form. Acquired LQTS is more frequent than the heritable form. In some instances, it may be 
challenging to differentiate the heritable from acquired forms of LQTS because exposure to 
a trigger associated with acquired LQTS may uncover previously undiagnosed LQTS [18].
Prevalence of heritable LQTS in the US is approximately 1:2500 [19]. Sequence variants in 
LQTS genes are present at higher rates in sudden cardiac death cohorts without known heart 
disease [20]. Pathogenic sequence variants associated with cardiac ion channels or their 
underlying structural or trafficking apparatus can cause heritable LQTS with three genes 
(responsible for LQTS subtypes 1–3) responsible for approximately 90% of genotype-
positive LQTS and another 12 genes accounting for <5% of the remaining cases [7, 9, 13]. 
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LQTS is typically autosomal dominant, but a rare form, Jervell-Lange Nielsen syndrome, is 
autosomal-recessive with a prevalence of ~1 in 4 million.
Approximately 50% of patients manifest non-specific symptoms associated with LQTS. 
Determination of a prolonged QT interval by an electrocardiogram (ECG) provides a 
definitive result but this test lacks sensitivity. Approximately 25% of patients diagnosed with 
LQTS have a normal QT interval at the time of testing [19, 21]. Genetic testing in 
combination with family history can assist in the diagnosis of heritable LQTS [10, 22] and 
identifying other family members at risk. Genetic testing is also useful to confirm or identify 
subtypes of LQTS that may inform the type of therapy administered (Table 1). Therapies 
include modification of exercise, avoidance of triggering stimuli, avoidance of QT 
prolonging medications, prescription of beta-blockers, placement of implantable cardioverter 
defibrillators, and surgical left cervicothoracic sympathetic ganglionectomy.
Walking through an LQTS diagnosis
It is instructive to walk through the diagnostic workflow depicted in Figure 1 after which a 
more in-depth discussion is presented that will explore the complexity of DNA testing as a 
component of the diagnostic process and insights useful for clinical practitioners. A 
hypothetical, but realistic, patient illustrates the application of the workflow.
Initial presentation
The clinical scenario begins with a 17-year-old male with loss of consciousness during 
basketball practice. He regains consciousness quickly and is evaluated in the emergency 
department (ED) at the local hospital. He says he takes no medication and is not aware of 
familial heart disease. The parents confirm this. There is no evidence of dehydration. ECG 
and electrolyte measurements are normal. The ED physician refers the patient to outpatient 
Cardiology and Neurology.
Outpatient follow-up
For the hypothetical patient, a neurologist found no evidence of neurologic cause. At the 
cardiology consult, parents are present. The patient has no prior medical history relevant to 
loss of consciousness. However, the cardiologist discovers the potential for a relevant family 
history for LQTS in learning about an uncle that died in an unprovoked collision involving a 
single vehicle who had a son that died in a witnessed pool drowning. Consultation with the 
physician who treated the uncle did not reveal any indication of an evaluation for a cardiac 
condition.
The patient’s ECG and echocardiogram test results are normal. The echocardiogram rules 
out structural heart disease and cardiomyopathy leaving arrhythmias, secondary to 
channelopathies that include LQTS, higher on the differential diagnosis. With the available 
clinical and family history data, a risk (Schwartz) score is calculated to estimate the 
likelihood of LQTS that for this case is low to intermediate [23]. Follow-up exercise testing 
(non-resting ECG) of the patient is equivocal. Because LQTS and several other arrhythmias 
are heritable, ECG testing of the parents may provide evidence for familial disease. Parental 
results are equivocal. The next step in the diagnostic workflow is Holter monitoring that 
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collects ECG data continuously for a period of 12–24 h [11]. In this hypothetical scenario, 
Holter monitoring does not resolve the diagnostic odyssey. These negative results reduce, 
but do not eliminate, clinical suspicion for LQTS.
Genetic testing with counseling is the final step in the workflow. Genetic testing can identify 
disease-associated sequence variants within genes associated with various arrhythmias that 
include LQTS. Discovering a pathogenic LQTS sequence variant supports a diagnosis for 
LQTS. On the other hand, the absence of a pathogenic finding does not exclude a diagnosis 
for LQTS.
Discussion
The emergency department encounter
Diagnosis, triage, and treatment of health conditions requiring immediate treatment is the 
primary focus of ED physicians. Diagnosing LQTS in the absence of physiological 
indications is challenging. ED clinicians do not generally have the time to collect a detailed 
family history because of competing priorities and multiple patients requiring the attention 
of ED clinicians [24, 25]. Molecular genetic tests for cardiac conditions are not typically 
ordered in ED settings because they do not inform management decisions in a timely 
manner and other, immediately useful, testing modalities are available (e.g. ECG). The ED 
physician refers the hypothetical patient to specialists for follow-up because clinical 
suspicion remains for a potentially serious health condition related to the patient’s 
presentation.
The outpatient encounter with a cardiologist
The cardiologist collects a detailed family history at the beginning of the encounter. 
Cardiologists and many specialists receive training to recognize such clues as in our scenario 
where the single car collision and witnessed drowning raise suspicion for a familial cardiac 
condition. A family history may also be useful to identify relatives potentially affected with 
an arrhythmia from information provided by the patient. Acquiring a relative’s medical 
information contained within their medical record to learn more is possible but can be 
challenging because policies at the patient’s and relative’s medical practice may restrict 
access until informed consent from the relative(s) is obtained and administrative processes 
completed. From a US federal regulatory perspective, the Health Insurance Portability and 
Accountability Act of 1996 (45 C.FR § 164.506) allows but does not require healthcare 
providers to voluntarily choose to obtain an individual’s consent for it to use and disclose 
information about him or her for treatment, payment, and healthcare operations. Consulting 
with a genetic counselor can serve to expedite these processes. These professionals have 
specialized training to serve as a bridge between institutions, clinicians, patients, relatives, 
and administrators to facilitate informed consent processes and gain access to clinical data. 
For clinicians not having ready access to these professionals, the National Society of Genetic 
Counselors (http://www.nsgc.org, accessed May 22, 2019) links healthcare providers to 
genetic counselors as one of its services.
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ECG results from the patient’s parents can be useful toward identifying a familial condition. 
A parent diagnosed with LQTS raises the prospect and increases the pretest probability for 
the patient having this condition but in itself is not diagnostic for the patient [26]. Such 
testing may not be readily available for the parents. For example, access to testing can vary 
because insurers may not reimburse for this service. On the other hand, asymptomatic 
parents who are tested and diagnosed with a potentially serious cardiac condition may find 
access and cost to life insurance affected. Therefore, it is important to inform the parents 
about these issues related to the benefits and risks of potential findings.
Holter monitoring assesses the risk for an arrhythmia typically over a period of one or more 
days when other means have failed to identify the problem. While this seems ideal for a 
dynamic condition like LQTS, studies are lacking that describe the utility of Holter 
monitoring in terms of the diagnostic yield [8, 11].
The efficacy of available therapies for LQTS vary by disease subtype. ECG, including T-
wave morphology and QT responses to exercise, can identify certain LQTS subtypes. 
Genetic test findings are also useful for assigning disease subtypes, which for LQTS may 
also direct genotype-specific medical therapy in some cases.
A presumptive diagnosis of LQTS is sufficient to prescribe therapy. Elements of the clinical 
presentation, family history, and physiologic test results can inform the making of a 
presumptive diagnosis in the absence of a definitive ECG result. A definitive diagnosis is 
sufficient to begin identifying other family members at risk for LQTS. Genetic testing 
results can confirm, but not preclude, a diagnosis for LQTS in the presenting patient [15, 19, 
27]. Sequence analysis may also identify variants of unknown significance. As our 
understanding about the genetics of arrhythmias builds over time, the number of variants of 
unknown significance will likely decrease. This raises the question regarding whether a 
patient lacking a definitive genetic diagnosis requires periodic reevaluation to account for 
new knowledge. The American College of Medical Genetics and Genomics released a 
Points-to-Consider statement that addresses reevaluation and reanalysis of genomic test 
results. One perspective shared is the need for clinical laboratories to respond to external 
requests for reevaluation or reanalysis in a timely manner and having policies that reflect 
this (https://www.nature.com/articles/s41436-019-0478-1.pdf, accessed May 22, 2019).
Selection and ordering of the molecular genetic test for LQTS
Selection of the appropriate genetic test for LQTS can be challenging because of the 
multiple tests available, many differing by the number of LQTS-relevant and other 
arrhythmia/cardiac genes interrogated (Figure 2). For LQTS, approximately 90% of disease-
associated variants occur in the three canonical LQTS-causative genes. These are included in 
the majority of gene panels listed within the Genetic Testing Registry (https://
www.ncbi.nlm.nih. gov/gtr, accessed May 22, 2019), a database to which clinical 
laboratories can submit information about the tests they offer [28]. As of 2019, gene panel 
testing is the most common type of test offered according to the Genetic Testing Registry. 
As of 2019, there were 24 laboratories listed within the United States offering molecular 
genetic testing for LQTS. Data entry is voluntary, raising the likelihood that there are 
additional laboratories offering LQTS testing in the US.
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Choosing the best test for a given patient requires consideration of the clinical presentation, 
family history, potential differential diagnoses, and knowledge of the genes included within 
the test panels under consideration. Laboratory expertise and resources (e.g. information on 
website) can be helpful to gain an understanding of the tests available, their uses, and 
limitations, prior to test ordering. Costs and turn-around times vary and are additional 
considerations for the clinician ordering genetic tests. On the other hand, test selection often 
requires knowledge beyond the limits of the patient’s physician and a consultation with a 
laboratory professional, medical geneticist, or genetic counselor is useful. The extent to 
which clinicians know about or take advantage of this consultative role is not clear [29].
Clinical laboratories may review test orders for appropriateness but this can be challenging 
because the laboratory may not receive or otherwise have access to important clinical 
information about the patient and family. The absence of this information does not preclude 
performing the test. Without this information, the laboratory provides a generic 
interpretation that may not be optimal for informing clinical decisions [27]. For example, a 
laboratory may classify a variant as one of unknown significance in the absence of data to 
support a pathologic or benign classification. If in fact, there is evidence only available to the 
clinician that the finding is a pathogenic familial variant, a re-classification of the variant to 
pathogenic is in order.
Another factor in test selection is that physicians may be constrained to the tests they order 
because of limitations imposed by institutional contractual agreements and health insurance 
coverage. Testing outside contractual agreements, if permitted, often requires a justification 
that undergoes review. Studies are lacking that investigate the influence of these policies for 
making accurate and timely diagnoses. Costs and turn-around times vary and are additional 
considerations for the clinician ordering genetic tests.
Assigning clinical relevance to a sequence variant
For heritable conditions, such as LQTS, professional guidance is available for classifying 
sequence variants using a variety of criteria that categorize findings as pathogenic, likely 
pathogenic, benign, likely benign, or of unknown significance [30]. However, variation 
exists in the application of these criteria for classifying variants [31]. To reduce this 
variability, electronic variant classification tools are available that apply criteria in a uniform 
manner [32]. This reduces but does not eliminate variability. These processes use data from 
a number of databases. However, many of these databases primarily support research and are 
not curated to support clinical applications. One study reported misclassification of 27% of 
literature-annotated disease-associated mutations within a number of frequently accessed 
databases [33]. Consequently, professional judgment prevails in the assessment of the 
quality of data derived from these databases for clinical applications and may still require 
manual curation [34]. This is primarily an issue for the rarer sequence variants where 
published studies are limited or absent in the peer-reviewed literature. Nonetheless, 
experience and expertise in performing and reporting clinical sequence analyses can be an 
important factor in choosing the testing laboratory.
Recognizing the need for a credible and curated database, The National Center for 
Biotechnology Information (https://www.ncbi.nlm.nih.gov/clinvar/, accessed May 22, 2019) 
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developed a resource, Clinvar, which provides information about variants and their disease 
association [35]. As of April 2019, Clinvar contains approximately 408,000 entries having 
clinical assertions associated with many medical conditions.
Using genetic test results to inform patient management and identifying family members at 
risk
A genetic test for LQTS may find pathogenic or likely pathogenic sequence variants or 
variants of unknown significance. Laboratories typically do not report sequence variants that 
are benign or likely benign [34]. It is important for clinicians to review the laboratory’s test 
interpretation to determine consistency with the patient’s clinical presentation and family 
history. A discordance can lead to a change of a clinical classification of the variant, such as 
the example provided earlier where a variant classified to be of unknown significance was 
reclassified as pathogenic when previously determined to be a disease-associated familial 
sequence variant. As of 2019, guidance that covers clinician review of genetic test results is 
lacking. This emphasizes the need for clinicians less knowledgeable about genetics and 
genetic testing to collaborate with other experts such as laboratory professionals, genetic 
counselors, or medical geneticists who have the specialized knowledge needed to inform 
patient management decisions.
Role of health information technology
Health information technology is evolving to facilitate quality patient care and improve the 
clinical workflow. Perhaps of greatest interest is decision support systems developed to 
assist clinicians to order appropriate testing and aid in understanding and applying test 
results. Criteria evaluated in deciding to implement these tools include a clear understanding 
of benefits to the patient, ease of use, the influence on the clinical workflow, and the cost for 
implementation and maintenance. A model piloted at the Veterans Administration, Los 
Angeles as of 2019, is the delegation of electronically placed genetic test orders for review 
of clinical appropriateness by a clinical geneticist. When a test order was not relevant to the 
indication for testing or otherwise duplicative, a genetics consult was offered to discuss the 
appropriate testing regimen. This process led to a reduction in inappropriate test orders [36]. 
For result reporting, examples of decision support tools are emerging. Rasmussen et al. 
reported the use of a system to aid clinical decision making that receives and analyzes test 
results to generate a descriptive phenotype that is deposited into the patient’s electronic 
medical record [37]. Until such systems, or other solutions, gain broader use in the clinical 
realm, there will continue to be the need to access testing expertise when uncertainty exists 
about the uses and limitations of genetic tests and results.
Conclusions
The development and use of a diagnostic workflow provides the opportunity to assess the 
challenges, and approaches to consider when integrating genetic testing into a broader 
diagnostic evaluation. This exercise provides illustrative examples of challenges and 
consideration useful to clinicians, laboratory professionals, and others important to deriving 
an accurate and timely diagnosis for LQTS with relevance to other heritable conditions. The 
resources noted in Table 2 are intended to assist healthcare professionals in designing 
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setting-specific solutions to the challenges indicated, based upon the stated considerations. 
Access to current knowledge and practices relevant to the use of genetics within a diagnostic 
evaluation is a key element, considering the complexities and dynamic nature of genetics 
and genetic testing. The National Academies report, Improving Diagnosis in Health care, 
emphasizes the importance of patient engagement and informed decision-making [2]. For 
genetic conditions, this often brings issues relevant to the patient’s family into the diagnostic 
process. The increasing number and complexity of tests challenges clinicians to maintain 
current knowledge regarding the uses and limitations of testing. Engaging professionals with 
genetic testing expertise (e.g. genetic counselor, laboratory professional, physicians having 
specialized genetic knowledge) relevant to a particular medical discipline (e.g. cardiology) 
can be helpful to ensure appropriate test selections and application of the test results to 
patient care decisions.
The LQTS diagnostic workflow illustrates the importance for leveraging knowledge of 
cardiology, genetics, and laboratory medicine to support a timely and accurate diagnosis. 
The evolution and use of health information technology and clinical decision support tools 
will continue to have an important role for those who develop, implement, and use guidance. 
Equally or more important is effective consultation and collaboration among healthcare 
professionals and the patient in making accurate and timely diagnoses, particularly for 
clinical presentations that require expert input of clinical and laboratory professionals, as is 
the case for LQTS. The National Academies report recommends the use of a diagnostic 
management team to achieve this [2]. Such a team brings clinicians, lab scientists, and the 
patient together to determine the optimal diagnostic strategy for the patient. This contrasts to 
the typical care delivery model for patient referral, with minimal communication among 
treating physicians and laboratory professionals. Studies suggest that the use of diagnostic 
management teams can improve coordination of care among healthcare providers, decrease 
referral times, promote informed decision-making, and achieve higher-quality health 
outcomes [2, 38].
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Figure 1: The LQTS diagnostic workflow.
This diagram illustrates a diagnostic workflow for LQTS. This includes alternate pathways 
that depend on findings from a particular step in the process. The dotted lines indicate the 
diagnostic evaluation applicable to the hypothetical patient described in the manuscript.
Lubin et al. Page 12
Diagnosis (Berl). Author manuscript; available in PMC 2021 January 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2: 
Variation in molecular genetic tests among clinical laboratories. The Genetic Testing 
Registry (https://www.ncbi.nlm.nih.gov/gtr/, accessed May 22, 2019) provided data for this 
analysis. Gene panels target only LQTS or a broader set of arrhythmias and other non-
arrhythmogenic heritable cardiac disorders.
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Table 1:
Clinical Features, laboratory testing, and risk scoring for LQTS.
Clinial features
• Cardiac arrhythmias disorder of repolarization characterized by prolongation of the QT interval that can lead to:
– Polymorphic ventricular tachycardia
– Ventricular defibrillation
– Sudden cardiac death
• Unexplained syncope with
– Prolonged corrected QT interval (480–500 ms)
– Without reversible explanation
– Absence of a known pathogenic mutation
• Can be heritable or acquired (e.g. drug-induced)
• Heritable form is autosomal dominant
• Prevalence of heritable LQTS: ~1:2500
Diagnostic criteria and risk scoring
• Electrocardiogram to measure QT interval [A diagnosis can be made by a finding corrected for heart rate; >500 ms without 
reversible cause (e.g. external trigger such as drug or other environmental factor like hypothermia)]
• Genetic testing (to identify a pathogenic variant)
• Risk (Schwartz) scoring (combines several criteria, including ECG findings, clinical, and family history) that is used to determine 
the likelihood of a diagnosis of LQTS
Features of major LQTS subtypes
 General
• LQTS subtypes 1–3 are responsible for approximately 90% of genotype-positive LQTS
• 12 genes responsible for <5% of remaining LQTS cases
 LQT1
• The KCNQ1 gene on chromosome 11
• Associated with loss of function variant
• >50% attributed to pathogenic variants in this gene
• Exercise and emotional stress can precipitate an arrhythmic event
• Clinical response to beta blockers
 LQT2
• KCNH2/hERG gene on chromosome 7
• Associated with loss of function variant
• 35–40% attributed to pathogenic variants in this gene
• Arrhythmic events precipitated primarily by auditory stimuli
• Clinical response to beta blockers but less than for LQT1
 LQT3
• SCN5A gene on chromosome 3
• Associated with gain of function variant
• 10–15% attributed to pathogenic variants in this gene
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• Often exhibit arrhythmic events during sleep; definitive data lacking regarding effectiveness of beta blockers but thought less than 
LQT1 or LQT2
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